From Bench to bedside and back again-emerging opportunities
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
We believe that an exciting new era of innovative therapeutic advancement has already begun. Patients with severe chronic rheumatic diseases can realistically entertain the expectation of substantial symptomatic improvement, or even of cure. The excitement of both scientists and clinicians is highlighted in this edition of Best Practice and Research Clinical Rheumatology. The proof of principle that targeting cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), with biological reagents may lead to spectacular biological outcomes has led us to believe that some diseases might even be cured.
|Number of pages||2|
|Journal||Best Practice and Research: Clinical Rheumatology|
|Publication status||Published - Oct 2006|